Afsheen Iqbal is an Oncology physician. OpenAlex indexes 80 publications with 1,640 citations (h-index 12).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
136 Mountainview Blvd
Basking Ridge, NJ 079203444
Telephone
908-542-3300Registry record last updated 7 Aug 2013.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Regeneron Healthcare Solutions, Inc.Program year20242 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
30.3%Benzodiazepine13.1%Lorazepam58%Alprazolam42%Part D<11 patientsOpioid Agonist5.5%Tramadol Hcl100%Part D≥12 patients+ 4 more classes in this area
Cancer & immunology
25%Kinase inhibitor25%Tagrisso68%Erlotinib Hcl12%Retevmo11%Tabrecta10%Part D<11 patientsMetabolism & gastrointestinal
22.8%Serotonin-3 Receptor Antagonist7.9%Ondansetron Hcl100%Part D≥30 patientsProton pump inhibitor7.1%Pantoprazole Sodium69%Omeprazole31%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- MA01.06 Phase I/II Trial of Canakinumab With Chemoradiation and Durvalumab in Stage III Non-Small Cell Lung Cancer (CHORUS)
Journal of Thoracic Oncology
2025 - Phase II Trial of Concurrent Durvalumab and Radiation Therapy for Locally Advanced Lung Cancer
International Journal of Radiation Oncology*Biology*Physics
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”